GZMB and non-small cell lung carcinoma: For further validation, we performed a flow cytometry analysis using multiple antibodies, including anti-CD8, anti-CD103, and anti-GZMB for another validation set that consist of tumors from independent 35 NSCLC patients with EGFR-WT (n = 16) or EGFR-MT (n = 19) (Supplementary Data 5b).